lar MRD monitoring of ALL patients in Turkey (original) (raw)

Minimal Residual Disease (MRD) Detection with Translocations and T-Cell Receptor and Immunoglobulin Gene Rearrangements in Adult Acute Lymphoblastic Leukaemia Patients: A Pilot Study

Ümit Üre

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2008

View PDFchevron_right

Minimal residual disease ( MRD ) detection with translocations and T-cell receptor and immunoglobulin gene rearrangements in adult acute lymphoblastic leukemia patients : a pilot study

Ugur Ozbek

2008

View PDFchevron_right

Minimal Residual Disease (MRD) in Leukemia

Irina Trandafir

2016

View PDFchevron_right

Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients

Yasutaka Kakinoki, Takeshi Kondo

American Journal of Hematology, 2005

View PDFchevron_right

Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia

Giovanni Cazzaniga

British Journal of Haematology, 2011

View PDFchevron_right

Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India

Rajesh Bhola

Indian Journal of Hematology and Blood Transfusion, 2019

View PDFchevron_right

Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia

sevgi yetgin

British Journal of Haematology, 2002

View PDFchevron_right

Minimal residual disease diagnostics in acute lymphoblastic leukaemia: impact of primer characteristics and size of junctional regions

Alberto Orfao

British Journal of Haematology, 2013

View PDFchevron_right

Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL

Vassilis Vasdekis

Leukemia & lymphoma, 2018

View PDFchevron_right

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

Grazia Fazio

Leukemia

View PDFchevron_right

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches

Owen Smith, Prerna Tewari

British Journal of Haematology, 2009

View PDFchevron_right

Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience

A. Cizmar

Neoplasma, 2010

View PDFchevron_right

Detection of minimal residual disease in pediatric patients with acute lymphoblastic leukemia and its prognostic significance

Gunnur Deniz

World J Pediatr, 2007

View PDFchevron_right

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group

Arcangelo Liso

Leukemia, 2000

View PDFchevron_right

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

T. Klingebiel

Bone Marrow Transplantation, 2003

View PDFchevron_right

Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia

Francesco Fabbiano

British Journal of Haematology, 2003

View PDFchevron_right

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

Chantal Brouzes

Leukemia, 2012

View PDFchevron_right

Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic Leukemia

Rosemary Sutton

The Journal of Molecular Diagnostics, 2009

View PDFchevron_right

Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR)

Sigal Manor

Pediatric Blood & Cancer, 2009

View PDFchevron_right

Competitive PCR for quantification of minimal residual disease in acute lymphoblastic leukaemia

Lars P Ryder, Finn Wesenberg

Journal of Immunological Methods, 2000

View PDFchevron_right

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia

Alessandra Santoro

Leukemia & Lymphoma, 2019

View PDFchevron_right

Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols

Alexander Meleshko, Olga Aleinikova, Olga Krasko

Leukemia Research, 2011

View PDFchevron_right

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Helene Cave

Leukemia, 2009

View PDFchevron_right

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Adriana Plesa

Blood

View PDFchevron_right

The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood

Sim-Hee Neoh

Leukemia, 1997

View PDFchevron_right

Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia

Anuruddhika Dissanayake, Rosemary Sutton

View PDFchevron_right

Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia

Michael Brisco, Alexander Morley

British Journal of Haematology, 1997

View PDFchevron_right

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell recepto...

Helene Cave

Haematologica, 2017

View PDFchevron_right

Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia

F. Behm

Leukemia, 1999

View PDFchevron_right

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

Simone A Joosten

Leukemia, 2001

View PDFchevron_right

Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid Leukemia

Francesco Buccisano

Journal of Hematotherapy & Stem Cell Research, 2002

View PDFchevron_right